ロード中...
Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma
Introduction: The appraisal of medicines is often a complex and iterative process. We compared the health technology assessment (HTA) process in England and France taking as a case study the example of ixazomib for multiple myeloma. Methods: We undertook an analysis of eight relevant published docum...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2019-01-01
|
| シリーズ: | Journal of Market Access & Health Policy |
| 主題: | |
| オンライン･アクセス: | http://dx.doi.org/10.1080/20016689.2019.1648971 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|